BioXcel Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker BTAI. Headquartered in New Haven, Connecticut, United States, the company was incorporated in 2017 and was built around a differentiated strategy: using artificial intelligence and data-driven methods to accelerate drug discovery and development, especially in neuroscience. For French-speaking investors in France, Belgium, and Switzerland, BioXcel fits the profile of a high-risk, high-upside biotech story, where valuation is driven less by current sales and more by clinical execution, regulatory milestones, and the optionality of future label expansions. The company’s lead and most advanced asset is BXCL501, commercialized as IGALMI®, a sublingual dexmedetomidine film approved in the United States for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. FDA approval in 2022 established BioXcel’s first commercial product and validated the company’s neuroscience-focused platform. Since then, management has pursued additional development paths, including a supplemental NDA aimed at expanding IGALMI into the at-home or outpatient setting. BioXcel is also advancing late-stage clinical programs for BXCL501 in agitation associated with Alzheimer’s dementia and related neuropsychiatric settings. BioXcel’s history is tied to BioXcel LLC and a broader AI-enabled drug-development concept that combined machine learning with clinical and translational expertise. Over time, the company narrowed its focus toward the most promising neuroscience programs, particularly BXCL501, while keeping a relatively lean operating structure. That strategic refocus has also translated into a strong emphasis on liquidity management, cost discipline, and governance refreshes, reflecting the capital-intensive nature of biotech development. From a competitive standpoint, BioXcel operates in a market with substantial unmet need. Acute agitation in schizophrenia, bipolar disorder, and dementia is clinically significant, yet treatment options remain limited and often based on older standards of care. BioXcel’s differentiation lies in its formulation, intended onset profile, and potential use across settings, including institutional and potentially at-home care. That said, it competes not only with existing therapies used in practice, but also with the possibility of new entrants if the category expands. Its geographic footprint is mainly U.S.-focused, with headquarters and core operations in the United States. Recent company highlights include FDA acceptance of a supplemental NDA for IGALMI in the at-home setting, ongoing progress in the SERENITY and TRANQUILITY trials, and a steady stream of SEC filings including Form 4 insider transaction reports. These developments underscore a company that is still largely in execution mode: BioXcel is trying to convert one approved product into a broader franchise while preserving enough financial flexibility to support its pipeline. For equity investors, BTAI remains a speculative healthcare name with meaningful binary catalysts and a valuation highly sensitive to clinical and regulatory outcomes.